acut
respiratori
failur
immunosuppress
respiratori
virus
polymeras
chain
reaction
assay
summari
purpos
prospect
singlecent
studi
assess
sensit
clinic
relev
molecular
test
respiratori
virus
critic
ill
immunocompromis
patient
acut
respiratori
failur
arf
method
consecut
critic
ill
immunocompromis
patient
arf
among
hematolog
malign
includ
hematopoiet
stem
cell
transplant
recipi
iatrogen
immunosuppress
solid
malign
multiplex
molecular
assay
mma
ad
usual
batteri
test
perform
look
caus
arf
result
nasopharyng
aspir
andor
bronchoalveolar
lavag
fluid
test
respiratori
virus
use
mma
immunofluoresc
viru
detect
patient
use
mma
patient
use
immunofluoresc
p
z
mmaposit
mmaneg
patient
similar
clinic
radiograph
present
significantli
differ
use
ventilatori
support
vs
p
z
occurr
shock
vs
p
z
use
renal
replac
therapi
vs
p
z
sap
ii
vs
p
z
time
spent
icu
vs
respiratori
medicin
day
p
z
icu
mortal
vs
p
z
use
mma
viru
found
patient
diagnosi
end
etiolog
investig
conclus
critic
ill
immunocompromis
patient
mma
far
sensit
immunofluoresc
respiratori
viru
detect
patient
rv
detect
respiratori
tract
clinic
characterist
outcom
patient
molecular
detect
respiratori
virus
immunocopromis
icu
patient
incid
mean
introduct
acut
respiratori
failur
arf
occur
patient
malign
high
risk
death
particularli
requir
mechan
ventil
respiratori
virus
rv
detect
e
arf
episod
togeth
bacteri
fungal
infect
often
seen
set
rv
infect
potenti
lifethreaten
immunocompromis
patient
viral
cultur
long
consid
refer
standard
diagnos
rv
infect
usual
take
sever
day
yield
result
antigen
detect
faster
less
sensit
molecular
screen
base
polymeras
chain
reaction
pcr
fast
sensit
earlier
test
method
highli
specif
capabl
detect
rhinovirus
coronavirus
miss
test
molecular
assay
report
improv
diagnost
yield
compar
convent
method
acut
respiratori
ill
patient
hematolog
malign
howev
detect
nucleic
acid
oppos
live
organ
clinic
relev
therefor
unclear
posit
molecular
assay
respiratori
sampl
may
indic
viral
infect
colon
contamin
purpos
studi
evalu
multiplex
molecular
assay
mma
compar
immunofluoresc
rv
detect
immunocompromis
patient
admit
intens
care
unit
icu
arf
assess
clinic
relev
mma
result
immunocompromis
patient
hypoxem
arf
admit
close
icu
teach
hospit
januari
juli
includ
prospect
cohort
studi
mma
intervent
institut
review
board
clermont
ferrand
teach
hospit
approv
studi
waiv
need
inform
consent
immunocompromis
statu
defin
presenc
diseas
treatment
known
impair
immun
system
hematolog
metastat
solid
malign
longterm
corticosteroid
therapi
immunosuppress
therapi
cytotox
chemotherapi
andor
bone
marrow
hematopoiet
stem
cell
transplant
hsct
patient
infect
human
immunodefici
viru
includ
arf
defin
respiratori
rate
greater
breath
per
minut
respiratori
distress
symptom
pao
room
air
lower
kpa
need
ventilatori
support
data
report
tabl
collect
studi
patient
simplifi
acut
physiolog
score
ii
sap
ii
time
icu
vital
statu
icu
discharg
also
collect
patient
investig
use
previous
describ
diagnost
strategi
reli
heavili
noninvas
test
patient
underw
noninvas
test
infect
sputum
examin
bacteria
mycobacteria
fungi
induc
sputum
pneumocysti
jirovecii
pneumonia
serum
blood
test
circul
cytomegaloviru
aspergillu
blood
cultur
specif
pcr
test
herp
virus
blood
respiratori
sampl
urin
test
bacteri
antigen
bronchoscopi
bronchoalveolar
lavag
bal
perform
deem
appropri
attend
physician
bal
fluid
collect
previous
describ
use
bacteri
mycobacteri
fungal
cultur
rv
antigen
detect
immunofluoresc
cytolog
examin
echocardiographi
chest
comput
tomographi
thoracocentesi
also
perform
deem
appropri
attend
physician
clinic
document
infect
defin
strong
clinic
radiograph
suspicion
pneumonia
without
microbiolog
document
either
septic
shock
complet
resolut
antibacteri
treatment
immunofluoresc
argen
verniol
franc
perform
routin
test
nasopharyng
aspir
npa
bal
fluid
influenza
b
virus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
adenovirus
human
metapneumoviru
hmpv
sought
start
octob
respiratori
specimen
also
investig
rv
use
mma
base
multiplex
ligationdepend
probeamplif
mlpa
technolog
pathofind
maastricht
netherland
allow
detect
differenti
respiratori
virus
includ
influenza
virus
b
rsv
b
rhinoviru
human
coronavirus
hmpv
adenoviru
addit
mma
detect
influenza
four
bacteria
chlamydophila
pneumonia
mycoplasma
pneumonia
legionella
pneumophila
bordetella
pertussi
sampl
store
c
extract
ml
intern
amplif
control
contain
encephalomyocard
viru
rna
transcript
ad
sampl
nucleic
acid
purifi
ml
sampl
easymag
system
biom
rieux
marci
letoil
franc
elut
ml
elut
buffer
use
amplif
three
step
preamplif
hybrid
ligationpcr
perform
themocycl
biorad
marn
la
coquett
franc
amplifi
mlpa
product
analyz
abi
genet
analyz
appli
biosystem
foster
citi
ca
fragment
size
analysi
perform
genemark
softwar
softgenet
llc
state
colleg
pa
two
clinician
review
medic
chart
studi
patient
determin
etiolog
arf
made
tabl
baselin
characterist
symptom
chest
radiographi
pattern
need
lifesupport
intervent
outcom
immunocompromis
patient
acut
respiratori
failur
comparaison
patient
without
posit
mma
basi
clinic
radiograph
microbiolog
histolog
find
accord
predefin
criteria
review
also
aim
evalu
clinic
signific
rv
detect
mma
patient
absenc
valid
criteria
mainli
base
presenc
absenc
definit
etiolog
arf
possibl
interplay
viral
infect
etiolog
quantit
paramet
report
median
interquartil
rang
iqr
percentil
qualit
paramet
number
percentag
categor
variabl
compar
use
c
test
fisher
exact
test
appropri
continu
variabl
compar
use
mannewhitney
u
test
wilcoxon
test
appropri
associ
patient
characterist
posit
mma
result
assess
use
logist
regress
model
multivari
analysi
perform
use
stepwis
forward
select
introduc
variabl
yield
p
valu
smaller
univari
analysi
also
introduc
variabl
seem
clinic
relev
absenc
signific
increas
likelihood
valu
omiss
remain
variabl
check
odd
ratio
or
confid
interv
ci
comput
p
valu
less
consid
signific
statist
analys
perform
use
statview
sa
institut
cari
nc
includ
immunocompromis
patient
admit
icu
arf
studi
period
main
characterist
list
tabl
median
symptom
durat
icu
admiss
day
admiss
leukocyt
count
l
patient
neutropenia
admiss
admiss
pao
kpa
mean
oxygen
rate
l
min
paco
kpa
ph
use
lifesupport
intervent
outcom
time
report
tabl
mma
perform
npa
patient
bal
fluid
immunofluoresc
posit
patient
mma
patient
p
z
tabl
exclud
rhinovirus
coronavirus
differ
remain
highli
signific
versu
p
coinfect
two
virus
detect
patient
use
mma
combin
influenza
rhinoviru
influenza
hmpv
influenza
adenoviru
influenza
b
adenoviru
piv
coronaviru
l
vs
l
respect
p
z
univari
analysi
posit
mma
associ
solid
organ
transplant
recipi
p
z
receiv
immunosuppress
past
month
p
z
test
npa
vs
p
z
variabl
significantli
associ
posit
mma
multivari
analysi
studi
patient
classifi
diagnost
categori
base
medic
chart
review
fig
mma
posit
patient
lung
infect
patient
noninfecti
lung
diseas
result
microbi
investig
given
tabl
coinfect
rv
bacteria
fungi
found
patient
infecti
lung
diseas
coinfect
describ
tabl
patient
consid
bacteri
fungal
lung
infect
patient
noninfecti
lung
diseas
respiratori
sampl
posit
coagulaseneg
staphylococci
coronaviru
pathogen
consid
signific
also
tabl
compar
mmaposit
mmaneg
patient
subgroup
without
lung
infect
subgroup
patient
noninfecti
lung
diseas
patient
diagnosi
found
end
etiolog
investig
multiplex
molecular
assay
posit
patient
among
immunocompromis
patient
admit
icu
arf
half
rv
detect
mma
rate
rv
detect
immunofluoresc
mma
still
significantli
higher
sensit
consid
virus
includ
immunofluoresc
panel
virus
detect
immunofluoresc
also
detect
mma
knowledg
first
mma
studi
immunocompromis
patient
arf
half
patient
least
one
rv
detect
mma
high
sensit
consist
result
previou
studi
hsct
recipi
acut
respiratori
ill
surprisingli
rhinovirus
rv
commonli
detect
mma
popul
rhinovirus
coronavirus
detect
immunofluoresc
fact
may
explain
higher
sensit
mma
howev
mma
remain
significantli
sensit
immunofluoresc
consid
rv
detect
method
whether
higher
sensit
rv
molecular
screen
improv
etiolog
diagnosi
arf
remain
uncertain
signific
posit
mma
immunocompromis
patient
arf
determin
data
studi
cohort
need
lifesupport
intervent
mortal
rate
low
mmaposit
patient
neither
significantli
differ
mmaneg
patient
clinic
radiograph
present
also
similar
posit
mma
neg
result
test
virus
associ
lower
viral
load
fewer
respiratori
symptom
compar
concomit
detect
mma
test
thu
pcrbase
method
may
help
detect
asymptomat
mildli
symptomat
stage
rv
infect
studi
establish
rv
includ
piv
hmpv
rhinovirus
sometim
detect
mma
respiratori
sampl
symptomfre
hsct
indic
asymptomat
rv
shed
occur
tabl
microorgan
use
lifesupport
intervent
outcom
patient
without
document
lung
infect
patient
without
posit
mma
respiratori
virus
rv
shed
last
longer
immunocompromis
patient
immunocompet
patient
posit
mma
may
mere
indic
low
level
shed
limit
clinic
signific
therefor
patient
posit
mma
may
indic
asymptomat
shed
unrel
caus
arf
final
mma
detect
nucleic
acid
rv
posit
mma
relat
sampl
contamin
subgroup
patient
without
document
lung
infect
posit
mma
associ
significantli
less
use
mechan
ventil
significantli
shorter
durat
hemodynam
failur
nonsignificantli
lower
valu
use
renal
replac
therapi
time
icu
icu
mortal
thu
immunocompromis
patient
arf
mma
may
identifi
patient
probabl
viral
pulmonari
involv
diagnosi
associ
better
outcom
assum
present
test
inconclus
inde
neg
test
caus
arf
constitut
major
diagnost
criterion
sever
noninfecti
condit
drugrel
pulmonari
toxic
pulmonari
infiltr
malign
consequ
mma
may
deserv
ad
list
investig
perform
routin
detect
caus
arf
nt
everi
effort
done
make
differ
posit
test
diagnost
test
contrast
subgroup
patient
lung
infect
signific
differ
mmaposit
mmaneg
patient
known
bacteri
fungal
lung
infect
identifi
rv
probabl
major
impact
manag
strategi
patient
outcom
rv
may
act
mere
risk
factor
infect
play
role
gener
arf
either
alon
conjunct
bacteri
fungal
infect
final
higher
sensit
mma
compar
immunofluoresc
seem
limit
clinic
consequ
high
frequenc
rv
detect
appear
signific
impact
patient
present
outcom
may
particularli
true
cohort
critic
ill
patient
gain
insight
clinic
signific
posit
mma
routin
perform
mma
bal
fluid
npa
andor
obtain
lung
biopsi
might
interest
histolog
show
cytopath
effect
lack
sensit
posit
result
difficult
interpret
criteria
avail
determin
causal
role
rv
lung
diseas
high
viral
load
often
accompani
clinic
diseas
low
viral
load
exclud
clinic
diseas
due
viru
moreov
pathogenesi
viral
infect
depend
intrins
viral
pathogen
also
genet
host
factor
involv
immun
respons
rhinovirus
particular
clinic
manifest
may
reflect
immun
respons
infect
rather
viral
cytopath
effect
prospect
cohort
immunocompromis
patient
admit
icu
arf
mma
far
sensit
immunofluoresc
rv
detect
clinic
characterist
outcom
significantli
differ
mmaposit
mmaneg
patient
howev
mma
suggest
altern
diagnos
noninfecti
lung
diseas
studi
evalu
diagnost
strategi
translat
improv
diagnost
efficaci
increas
surviv
warrant
studi
support
grant
assistancepubliqu
de
pari
aom
nonprofit
institut
